BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-26@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: IDEAYA Biosciences — IDE196 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: IDE196 (Darovasertib) in Combinatio
 n With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma.\nSou
 rce: https://clinicaltrials.gov/study/NCT05987332\nhttps://catalystbrief.g
 irapphe.com/e/26?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/26?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
